Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

S. Mitsuoka



Author of

  • +

    P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 692)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
    • Presentations: 1
    • +

      P1.06-014 - Higher Body Mass Index Prolongs Survival Time in Non-Small Cell Lung Cancer with Good Performance Status (ID 9657)

      09:30 - 09:30  |  Author(s): S. Mitsuoka

      • Abstract

      Background:
      Obesity is the accumulation of body fat that has a harmful effect on health and has been increased the risk and mortality of multiple diseases, such as cardiovascular diseases and diabetes. Obesity has been associated with increased risk and mortality of most cancers. On the other hand, obesity is associated with decreased risk of a part of lung cancer. The mechanism to decrease risk of lung cancer in obese individuals is not clear.

      Method:
      In our hospital, we retrospectively assessed 675 lung cancer patients who were hospitalized for the first time from April 2012 to July 2015. We collected patient data of baseline characteristics, histology, performance status (PS), body mass index (BMI), stage, smoking history, molecular profiling for EGFR, ALK. Patients were stratified into 3 BMI groups based on the WHO classification: underweight (< 18.5 kg/m[2]), normal weight (18.5 to < 25 kg/m[2]), and overweight (≥ 25 kg/m[2]). The classification of obese (≥ 30 kg/m[2]) was included in the overweight group in this study. Overall survival was calculated using the Kaplan-Meier method. We compared overall survival between BMI groups using log rank test.

      Result:
      In this retrospective cohort study, we assessed 566 patients with non-small cell lung cancer (NSCLC) and 109 patients with small cell lung cancer (SCLC). There were no significant differences in patient characteristics except for smoking history. In SCLC patients, there was no significant difference in overall survival by each BMI group (good PS [0 – 1] group, p = 0.186; poor PS [2 – 4] group, p = 0.809). In NSCLC patients with good PS, overall survival was prolonged in the order of the standard group and the overweight group, in comparison with the underweight group (p = 0.031). In NSCLC patients with poor PS, there was no significant difference in overall survival by each BMI group (p = 0.401). In NSCLC patients with good PS, higher BMI and activating EGFR mutation were associated with longer overall survival in a multivariate analysis (BMI: hazard ratio 0.468, 95% CI 0.253 – 0.855, p = 0.0136; EGFR mutation: hazard ratio 0.476, 95% CI 0.279 – 0.796, p = 0.0044). In SCLC patients with good PS, there was a tendency of longer overall survival in the overweight group than in the underweight group.

      Conclusion:
      Overweight in NSCLC patients with good PS had significantly improved overall survival.

  • +

    P3.01 - Advanced NSCLC (ID 621)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P3.01-088a - Phase II Study of Nab-Paclitaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: SNIPER Study (ID 9803)

      09:30 - 09:30  |  Author(s): S. Mitsuoka

      • Abstract

      Background:
      Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an albumin-bound formulation of paclitaxel. This single-arm, phase II trial evaluated nab-paclitaxel monotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC).

      Method:
      In this multicentre, single arm phase II trial, we enrolled patients with advanced NSCLC who had previously treated more than one chemotherapy regimen. Patients received nab-paclitaxel 80 mg/m[2] days 1, 8, and 15 (21-day cycle). The primary endpoint was investigator-assessed overall response rate (ORR); secondary endpoints included overall survival (OS), progression-free survival (PFS), the disease control rate (DCR), and safety. The planned enrollment was 30 patients by Simon 2-stage minimax design.

      Result:
      We enrolled 30 patients. We analyzed endpoints about initially enrolled 24 cases that were available for the evaluation now. Sixty-three % of patients had previous treatment more than 2 regimens. The ORR and DCR were 25% (95% CI 8-42%) and 75%, respectively. Median PFS and OS were 5.8 months and 9.8 months, respectively. No new safety signals were reported; the most common grade ≥3 adverse events included neutropenia (54%), leukopenia (9%), and infection (13%).

      Conclusion:
      In patients with heavily advanced NSCLC, nab-paclitaxel demonstrated promising antitumor activity; further assessment of nab-paclitaxel monotherapy in this population of patients is supported.